fda warning letters glp-1 compounding september 2025 Warns Novo Nordisk on Unreported Deaths FDA issues 30 warning letters

Curr Diabetes Rev 14(3):273279 Mousavi A et al (2025) Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

We've found that patients who attempt to extend WFI-reconstituted Lipo C beyond 48 hours report injection site reactions (erythema, induration, localised warmth) in approximately 3040% of cases

C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

Despite its name, subsequent research shows it normalizes disrupted sleep architecture rather than simply inducing sleepeffects are state-dependent, with greatest benefit in insomniacs

Xu X, Wang C, Zhang P, Gao X, Guan W, Wang F, et al